Thrombotic complications after intravenous immunoglobulin therapy in two patients

Pharmacotherapy

Volumn 22, Issue 12 I, 2002, Pages 1638-1641

  Emerson, Geoffrey G ^a   Herndon, Christopher N ^b   Sreih, Antoine G ^b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL OF SAINT RAPHAEL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; WARFARIN;

ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DISEASE COURSE; DOSE RESPONSE; FEMALE; HEMIPARESIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; LUNG EMBOLISM; RECURRENT DISEASE;

ADULT; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0036895518     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.17.1638.34125     Document Type: Article

References (22)

1. Nydegger UE. Safety and side effects of i.v. immunoglobulin therapy. Clin Exp Rheum 1996;14(suppl 15):S53-7.
2. Rathco TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA. Recommendations of off-label use of intravenously administered immunoglobulin preparations. JAMA 1995; 273:1865-70.
3. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
4. Kurlander R, Coleman RE, Moore J, Gockerman J, Rosse W. Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. Am J Med 1987;83(suppl. 4a):17-24.
5. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment o[of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients [letter]. Lancet 1986;2:217-18.
6. Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;2:257-8.
7. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994;44:1180-1.
8. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-7.
9. Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology 1996;46:250-1.
10. Oh KT, Boldt C, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 1997;124:416-18.
11. Scott-Moncrieff JCR, Reagan WJ, Snyder PW, Gickman LT. Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc 1997;210:1623-7.
12. Sztajzel R, Le Floch-Rohr J, Eggimann P. High-dose intravenous immunoglobulin treatment and cerebral vasospasm: A possible mechanism of ischemic encephalopathy? Eur Neurol 1999;41:153-8.
13. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: Case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000;75:83-5.
14. Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak D. Pulmonary embolism after intravenous immunoglobulin. J Royal Soc Med 2001;94:187-8.
15. Rosenbaum JT. Myocardial infarction as a complication of immunoglobulin therapy. Arthritis Rheum 1997;40:1732-3.
16. Paolini R, Fabris F, Cella G. Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). Am J Hematol 2000;65:177-8.
17. Elkayam O, Paran D, Milo R, et al. Acute myocardial infarction associated with high-dose intravenous immunoglobulin infusion for autoimmune disorders: A study of four cases. Ann Rheum Dis 2000;59:77-80.
18. Haplea SS, Farrar JT, Gibson GA, Laskin M, Pizzi JT, Asbury AK. Thromboembolic events associated with intravenous immunoglobulin therapy [abstr]. Neurology 1997;48:A54.
19. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662-4.
20. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology 1994;44:223-6.
21. Diz-Kucekkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: A prospective cohort study. Blood 2001;98:1760-4.
22. Shiozawa Z, Ueda R, Mano T, Tsugane R, Kageyama N. Superior sagittal sinus thrombosis associated with Evans' syndrome of haemolytic anaemia. J Neurol 1985;232:280-2.